

Serial No. 10/018,377

REMARKS

This paper is responsive to the Final Office Action mailed January 28, 2004. Claims 1-14, 18-23, and 25-32 remain in this application. Claims 1, 3, 6, 7-13, 23 and 25 have been amended. No new matter has been introduced into the claims. Reconsideration of the subject application in light of the amendments herein and the remarks that follow is respectfully requested.

The Pending Claims are Fully Enabled for Purposes of 35 U.S.C. § 112, First Paragraph


The Examiner has rejected Claims 1, 3, 6, 7, and 23 for nonenablement of an insulin analog, a derivatized insulin, or a derivatized insulin analog. Pursuant to a telephonic interview with Examiner's supervisor, Christopher Tate, Applicants have amended said claims according to Mr. Tate's suggestions. The undersigned thanks the Examiner for granting the interview request. Applicants believe that these amendments place the present application in condition for allowance, and respectfully request that this rejection be withdrawn.

Serial No. 10/018,377

SUMMARY AND CONCLUSION

In view of the remarks and amendments enclosed and provided herein above, it is respectfully submitted that Examiner's rejections have been overcome. Applicants request reconsideration and withdrawal of the rejections. If Examiner feels that a telephone conversation with Applicants' attorney would be helpful in expediting prosecution of this case, the Examiner is invited to call Applicants' attorney.

Respectfully submitted,



Caren D. Geppert
Attorney for Applicants
Registration No. 54,117
Phone: 317-651-4215

Eli Lilly and Company
Patent Division
P.O. Box 6288
Indianapolis, Indiana 46206-6288
